Panel of Serum Biomarkers May Predict Benefit from Bevacizumab (BEV) in Advanced NSCLC Patients
Eduardo Braun , Mary Jo Fidler , Sanjib Basu , Anjali Gargaram
JOURNAL OF THORACIC ONCOLOGY 7 ( 7) S124 -S125
2012
Home Evolving Standards of Care Patient, Provider Safety Paramount During Pandemic: Telehealth Benefits Are Numerous
Mary Jo Fidler
Home Evolving Standards of Care An Early Look at Adjuvant Osimertinib Shows a Dramatic Improvement in Disease-Free Survival
Mary Jo Fidler
An Early Look at Adjuvant Osimertinib Shows a Dramatic Improvement in Disease-Free Survival
Mary Jo Fidler
Abstract| PDF| Full Text| Order a Reprint| https://doi. org/10.18632/oncoscience. 72
Neeta Somaiah , Mary Jo Fidler , Elizabeth Garrett-Mayer , Amy Wahlquist
Treatment of advanced squamous cell carcinoma of the lung: a review
Marta Batus , Mary J. Fidler , Benjamin A. Derman , Philip D. Bonomi
Translational lung cancer research 4 ( 5) 524 -532
46
2015
Abstract PS11-07: Intratumoral activation and phase 1/2 clinical activity of CX-2009, a probody drug conjugate (PDC) targeting CD166
Ivan A. Zein , Susan K. Lyman , Tobias Arkenau , Virginia Paton
Cancer Research
2021
Association of biomarkers of insulin resistance and inflammation with PET CT SUV values in stage IV non-small cell lung cancer (NSCLC).
Benjamin Avi Derman , Jeffrey Allen Borgia , Cristina L. Fhied , Sanjib Basu
Journal of Clinical Oncology 34
2016
Cachexia Index utilization in patients with non-small cell lung cancer.
Douglas William Rybar , Ronald Ng , Mary J. Fidler , Samantha Kerns
Journal of Clinical Oncology 34
2016
Two year progression free survival in stage IV NSCLC patients treated with pemetrexed continuation maintenance.
Jason Nathaniel Macklis , Fatima Saleem , Fatema Mohammed Esmail , Sanjib Basu
Journal of Clinical Oncology 34
2016
Association of acute phase proteins with a serum proteomic test in previously treated patients with NSCLC.
Jeffrey Allen Borgia , Philip Bonomi , Jennifer Garrus , Fatima Saleem
Journal of Clinical Oncology 34
2016
Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010.
Edward B. Garon , Roy S. Herbst , Dong-Wan Kim , Enriqueta Felip
Journal of Clinical Oncology 34 9024 -9024
10
2016
Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1–Positive NSCLC.
Paul Baas , Edward B. Garon , Roy S. Herbst , Enriqueta Felip
Journal of Clinical Oncology 34 9015 -9015
9
2016
KRAS and P53 mutations and FDG-PET as a measure of glycolytic activity in metastatic non-small cell lung cancer patients.
Seo-Hyun Kim , Ammar Karo , Sanjib Basu , Jeffrey Allen Borgia
Journal of Clinical Oncology 34 ( 15_suppl) 9086 -9086
1
2016
Neutrophil to lymphocyte ratio as predictive of prolonged progression free survival (PFS) and overall survival (OS) in patients with metastatic non-small cell lung cancer (NSCLC) treated with second-line PD-1 immune checkpoint inhibitors.
Stephanie Labomascus , Ibtihaj Fughhi , Philip Bonomi , Mary J. Fidler
Journal of Clinical Oncology 35
9
2017
Circulating biomarkers and outcomes in advanced non-small cell lung cancer patients treated with anti-PD1 (program death 1 receptor) monoclonal antibodies.
Mary J. Fidler , Marta Batus , Imad Tarhoni , Selina Sayidine
Journal of Clinical Oncology 35
2017
Association of KRAS mutations detected via liquid biopsy in metastatic non-small cell lung cancer patients with high levels of FDG-PET SUV.
Seo-Hyun Kim , Ammar Karo , Lela Buckingham , Sanjib Basu
Journal of Clinical Oncology 35
1
2017
RM-1929 photo-immunotherapy in patients with recurrent head and neck cancer: Results of a multicenter phase 2a open-label clinical trial.
Ann M Gillenwater , David Cognetti , Jennifer Maria Johnson , Joseph Curry
Journal of Clinical Oncology 36 6039 -6039
6
2018
The prognostic value of neutrophil-to-lymphocyte ratio in patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer (NSCLC).
Nicole Yun , Sherin Juliet Rouhani , Brendan Gilmore , Ethan M. Ritz
Journal of Clinical Oncology 38 ( 15_suppl) e21675 -e21675
2020